Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Cannabidiol (CBD) has been investigated in a wide spectrum of clinical approaches due to its psychopharmacological properties. CBD has low affinity for cannabinoid neuroreceptors and agonistic properties to 5-HT receptors. An interaction between cannabinoid and purinergic receptor systems has been proposed. The purpose of this study is to evaluate CBD properties on memory behavioral and locomotor parameters and the effects of pre-treatment of adenosine receptor blockers on CBD impacts on memory using adult zebrafish. CBD (0.1, 0.5, 5, and 10mg/kg) was tested in the avoidance inhibitory paradigm and anxiety task. We analyzed the effect of a long-term caffeine pre-treatment (~20mg/L - four months). Also, acute block of adenosine receptors was performed in co-administration with CBD exposure in the memory assessment. CBD promoted an inverted U-shaped dose-response curve in the anxiety task; in the memory assessment, CBD in the dose of 5mg/Kg promoted the strongest effects without interfering with social and aggressive behavior. Caffeine treatment was able to prevent CBD (5mg/kg) effects on memory when CBD was given after the training session. CBD effects on memory were partially prevented by co-treatment with a specific A2A adenosine receptor antagonist when given prior to or after the training session, while CBD effects after the training session were fully prevented by adenosine A1 receptor antagonist. These results indicated that zebrafish have responses to CBD anxiolytic properties that are comparable to other animal models, and high doses changed memory retention in a way dependent on adenosine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 2×
“Caffeine is a known psychoactive drug with mnemonic effects credited to the non-specific antagonism of adenosine receptors (Fredholm et al., 1999; Cunha and Agostinho, 2010).”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Endocannabinoids are released during stressful conditions, and CB1 receptor agonism impairs the acquisition of contextual fear (Marsicano et al., 2002; Hohmann and Suplita, 2006).”
BackgroundDevinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000 · cited 1×
“However, several additional biological targets of CBDhave been identified (reviewed byDas et al., 2013; Devinsky et al., 2014).”
BackgroundAgonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497 · cited 1×
“Those complementary mechanisms of action proposed to underlie CBD action could explain some controversial results, such as the indirect agonistic effect on adenosine receptors, especially A2 receptors, by increasing adenosine levels as a response to nucleoside transport inhibition (Carrier et al., 2006; Liou et al., 2…”
BackgroundSmoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial
Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., & Atkinson, J. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.120 · Cited by 461 · cited 1×
“The analgesic effect could influence the sensibility to the inhibitory avoidance task, but the pharmacological base seems to be related to CB receptor activation, which is a weak property of CBD, while THC seems to be responsible for the analgesic property (Bushlin et al., 2010; Ellis et al., 2009; Grotenhermen and Mü…”
BackgroundCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 1×
“Much evidence suggests that CBD acts as an anticonvulsant, anxiolytic, antipsychotic, and antirheumatic (Carlini and Cunha, 1981; Hampson et al., 1998; Zuardi, 2008; Campos et al., 2013).”
BackgroundCampos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001502 · Cited by 313 · cited 3×
“Learning and memory appear to be affected by CBD through a mechanism including the endocannabinoid system (Marsicano and Lafenêtre, 2009; Campos and Guimarães, 2009; Campos et al., 2013).”
BackgroundMorgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305
Pamplona, F. A., Prediger, R. D. S., Pandolfo, P., & Takahashi, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0514-0 · Cited by 211 · cited 1×
“However, endocannabinoid signaling, especially through CB1 receptors, has been shown to cause impairment of memory acquisition in a contextual fear assessment and memory extinction (Pamplona et al., 2006; De Carvalho et al., 2014).”
BackgroundJohansson, B., Ahlberg, S., van der Ploeg, I., Brené, S., Lindefors, N., Persson, H., & Fredholm, B. B. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00165391 · Cited by 144 · cited 1×
“Long-term caffeine treatment has been associated with tolerance to locomotor effects attributed to the up-regulation or increasing in binding of A1 adenosine (Johansson et al., 1993; Jacobson et al., 1996), while mnemonic effects are more related to A2A adenosine receptor antagonism (Takahashi et al.”
BackgroundSoares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112
Self-citationCassol-Jr, O. J., Comim, C. M., Silva, B. R., Hermani, F. V., Constantino, L. S., Felisberto, F., Petronilho, F., Hallak, J. E. C., De Martinis, B. S., Zuardi, A. W., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.023 · Cited by 94 · cited 3×
“Despite thewell-known issue about anxiolytic properties of low-intermediary CBD doses, several studies have supported the use of a higher CBD dose as a protective substance against memory deficits induced by THC, inflammatory illness, and other memory-disruptive conditions (Cassol-Jr et al., 2010; Soares et al., 2010;…”
BackgroundResultSelf-citationFagherazzi, E. V., Garcia, V. A., Maurmann, N., Bervanger, T., Halmenschlager, L. H., Busato, S. B., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Schröder, N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2449-3 · Cited by 87
Self-citationBarichello, T., Ceretta, R. A., Generoso, J. S., Moreira, A. P., Simões, L. R., Comim, C. M., Quevedo, J., Vilela, M. C., Zuardi, A. W., Crippa, J. A., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.053 · Cited by 76
Self-citationCannabidiol attenuates deficits of visuospatial associative memory induced by Δ9tetrahydrocannabinol
Wright, M. J., Vandewater, S. A., & Taffe, M. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12199 · Cited by 72
Cited by
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
Self-citationZuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294
Self-citationCannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-0015 · Cited by 241
Self-citationThe endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11
Metadata
- Authors
- Nazario, L. R., Antonioli, R., Capiotti, K. M., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., Bonan, C. D., & da Silva, R. S.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 135
- Pages
- 210-216
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W584623554
- Cited by
- 46
- References
- 17
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.